An Updated Systematic Review on Remdesivir's Safety and Efficacy in Patients Afflicted With COVID-19.
antiviral drugs
covid-19
efficacy
remdesivir
sars-cov-2 treatment
Journal
Cureus
ISSN: 2168-8184
Titre abrégé: Cureus
Pays: United States
ID NLM: 101596737
Informations de publication
Date de publication:
Aug 2023
Aug 2023
Historique:
received:
31
05
2023
accepted:
06
08
2023
medline:
8
9
2023
pubmed:
8
9
2023
entrez:
8
9
2023
Statut:
epublish
Résumé
Globally, the coronavirus disease 2019 (COVID-19) had a significant impact on everyone's lives and put a tremendous strain on healthcare systems. Since the outbreak began, remdesivir has been investigated as a potential treatment for COVID-19 that may be both effective and safe. Remdesivir has had a huge impact on the disease's progression, complications, and mortality. This review provides an updated assessment of the literature regarding remdesivir's efficacy and safety for the treatment of patients with COVID-19. The search was performed through PubMed, Web of Science, Cochrane, and Scopus for articles published from 2019 to September 20, 2022. Studies that assessed remdesivir's efficacy and safety were included in this review, with clinical improvements as the primary outcome measure. Seventeen studies were identified following the implementation of the search strategy. Among them, 11 corroborated remdesivir's efficacy. Meanwhile, the remaining six studies did not observe a statistically significant difference in clinical improvement. Remdesivir is a potentially safe and effective antiviral that shows clinical improvement especially when used during the early course of the disease. However, current literature still questions its safety in patients who are afflicted with the complications of COVID-19, highlighting the need for studies on a large scale.
Identifiants
pubmed: 37680394
doi: 10.7759/cureus.43060
pmc: PMC10481368
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
e43060Informations de copyright
Copyright © 2023, Yasir et al.
Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Clin Infect Dis. 2020 Apr 27;:
pubmed: 32338708
Life Sci. 2021 Jan 1;264:118663
pubmed: 33121991
Lancet. 2020 May 16;395(10236):1569-1578
pubmed: 32423584
Am J Med Sci. 2022 May;363(5):403-410
pubmed: 35151637
Nat Commun. 2020 Oct 30;11(1):5493
pubmed: 33127906
CMAJ. 2022 Feb 22;194(7):E242-E251
pubmed: 35045989
BMJ. 2019 Aug 28;366:l4898
pubmed: 31462531
J Antimicrob Chemother. 2020 Nov 1;75(11):3359-3365
pubmed: 32829390
Biomed Pharmacother. 2020 Oct;130:110532
pubmed: 32707440
Clin Infect Dis. 2022 Aug 24;75(1):e450-e458
pubmed: 34596223
N Engl J Med. 2021 Feb 11;384(6):497-511
pubmed: 33264556
JAMA. 2020 Sep 15;324(11):1048-1057
pubmed: 32821939
BMJ. 2020 Sep 4;370:m3379
pubmed: 32887691
Cell Res. 2020 Mar;30(3):269-271
pubmed: 32020029
ANZ J Surg. 2003 Sep;73(9):712-6
pubmed: 12956787
Sci Transl Med. 2017 Jun 28;9(396):
pubmed: 28659436
BMJ. 2021 Mar 29;372:n71
pubmed: 33782057
Pharmacol Res. 2020 Aug;158:104899
pubmed: 32407959
J Chronic Dis. 1987;40(5):373-83
pubmed: 3558716
Open Forum Infect Dis. 2020 Aug 06;7(10):ofaa319
pubmed: 33117850
Clin Microbiol Infect. 2021 Jun;27(6):917.e1-917.e4
pubmed: 33705849
Indian J Anaesth. 2021 Mar;65(Suppl 1):S41-S46
pubmed: 33814589
Discoveries (Craiova). 2022 Jun 30;10(2):e151
pubmed: 36156901
Proc Natl Acad Sci U S A. 2020 Mar 24;117(12):6771-6776
pubmed: 32054787
Eur J Pharmacol. 2021 Apr 15;897:173926
pubmed: 33549577
Pol Arch Intern Med. 2021 Jan 29;131(1):103-110
pubmed: 33382547
N Engl J Med. 2020 Nov 5;383(19):1813-1826
pubmed: 32445440
J Glob Health. 2022 Aug 31;12:05031
pubmed: 36040909
N Engl J Med. 2020 Jun 11;382(24):2327-2336
pubmed: 32275812
Campbell Syst Rev. 2022 Mar 27;18(2):e1230
pubmed: 36911350
Lancet Infect Dis. 2022 Feb;22(2):209-221
pubmed: 34534511
JAMA Netw Open. 2021 Mar 1;4(3):e213071
pubmed: 33760094